HRT Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.12M | Buy |
124,620
+66,551
| +115% | +$596K | ﹤0.01% | 1018 |
|
|
2025
Q1 | $435K | Buy |
+58,069
| New | +$435K | ﹤0.01% | 1354 |
|
|
2024
Q4 | – | Sell |
-20,044
| Closed | -$152K | – | 2227 |
|
|
2024
Q3 | $152K | Buy |
+20,044
| New | +$152K | ﹤0.01% | 1848 |
|
|
2024
Q1 | – | Sell |
-292,412
| Closed | -$1.75M | – | 2201 |
|
|
2023
Q4 | $1.75M | Buy |
292,412
+79,714
| +37% | +$477K | 0.01% | 669 |
|
|
2023
Q3 | $1.51M | Buy |
212,698
+68,636
| +48% | +$486K | 0.02% | 697 |
|
|
2023
Q2 | $1.01M | Buy |
144,062
+81,839
| +132% | +$576K | 0.01% | 877 |
|
|
2023
Q1 | $518K | Buy |
+62,223
| New | +$518K | 0.01% | 1262 |
|
|
2022
Q4 | – | Sell |
-23,803
| Closed | -$299K | – | 2277 |
|
|
2022
Q3 | $299K | Buy |
+23,803
| New | +$299K | ﹤0.01% | 1868 |
|
|
2021
Q4 | – | Sell |
-126,125
| Closed | -$1.81M | – | 2894 |
|
|
2021
Q3 | $1.81M | Buy |
126,125
+7,575
| +6% | +$109K | 0.01% | 722 |
|
|
2021
Q2 | $1.87M | Buy |
118,550
+78,720
| +198% | +$1.24M | 0.02% | 622 |
|
|
2021
Q1 | $405K | Sell |
39,830
-261,852
| -87% | -$2.66M | ﹤0.01% | 1744 |
|
|
2020
Q4 | $2.25M | Buy |
+301,682
| New | +$2.25M | 0.05% | 278 |
|
|
2019
Q4 | – | Sell |
-77,424
| Closed | -$221K | – | 1097 |
|
|
2019
Q3 | $221K | Buy |
+77,424
| New | +$221K | 0.01% | 989 |
|
|
2015
Q3 | – | Sell |
-10,973
| Closed | -$163K | – | 90 |
|
|
2015
Q2 | $163K | Buy |
+10,973
| New | +$163K | 0.08% | 127 |
|